New Age Alpha Advisors LLC Sells 6,909 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• New Age Alpha Advisors LLC significantly reduced its stake in Regeneron Pharmaceuticals by 83.1%, now holding only 1,403 shares after selling 6,909 shares in Q1.
• Several institutional investors increased their investments in Regeneron, with Brighton Jones LLC boosting its stake by 261.8% in the fourth quarter.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, surpassing the consensus estimate by $4.46, demonstrating strong financial performance.

New Age Alpha Advisors LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 83.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,403 shares of the biopharmaceutical company's stock after selling 6,909 shares during the quarter. New Age Alpha Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $890,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the last quarter. Tompkins Financial Corp bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. Curat Global LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. Finally, American National Bank & Trust acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $44,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on REGN. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. Finally, Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a report on Friday, April 25th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $841.30.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded up $3.20 during mid-day trading on Friday, hitting $563.00. 1,024,297 shares of the stock were exchanged, compared to its average volume of 978,475. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm's 50-day simple moving average is $536.80 and its 200 day simple moving average is $598.52. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The stock has a market capitalization of $59.67 billion, a price-to-earnings ratio of 14.19, a price-to-earnings-growth ratio of 1.91 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the business posted $11.56 EPS. The business's revenue was up 3.6% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.